1. Revision of guidelines 12
2. Work of international bodies concerned with controlled substances 13

3. Critical review of psychoactive substances 14
3.1 Substance recommended for change in scheduling γ-Hydroxybutyric acid (GHB)
3.2 Other substance critically reviewed Ketamine (INN)

4. Pre-review of psychoactive substances 17
4.1 Dextromethorphan (pINN)
4.2 Tapentadol (INN)
4.3 Piperazines
4.3.1 N-Benzylpiperazine (BZP)
4.3.2 1-(3-Trifluoromethylphenyl)piperazine (TFMPP)
4.3.3 1-(3-Chlorophenyl)piperazine (mCPP)
4.3.4 1-(4-Methoxyphenyl)piperazine (MeOPP)
4.3.5 1-(3,4-Methylenedioxybenzyl)piperazine (MDBP)
4.4 γ-Butyrolactone (GBL)
4.5 1,4-Butanediol (1,4-BD)

5. Issues identified for consideration at future ECDD meetings 23

6. Other matters 24
6.1 Use of terms
6.2 Use of pharmacovigilance data for the assessment of abuse and dependence potential
6.3 Balancing medical availability and prevention of abuse of medicines manufactured from controlled substances
6.4 Improving the process for substance evaluation

Annex: Developments in terminology: the drug treaties, scheduling criteria, and diagnostic terms